# Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia

> **NCT00066326** · PHASE1 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute**

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** imatinib mesylate
- **DRUG:** tanespimycin

## Key facts

- **NCT ID:** NCT00066326
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2004-10
- **Final completion:** 2005-09
- **Target enrollment:** — (—)
- **Last updated:** 2013-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00066326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00066326, "Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00066326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*